Clinical Trial Update: Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity and safety of GlaxoSmithKline's combined measles-mumps-rubella vaccine in volunteers aged seven years and older; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• MMR vaccine (GlaxoSmithKline) (Measles, Mumps and Rubella vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rubella, Mumps | Phase 3 | Status: COMPLETED | Results posted: 2017-04-10